The Open Cardiovascular Medicine Journal

ISSN: 1874-1924 ― Volume 14, 2020

Stroke Prevention in Atrial Fibrillation and Valvular Heart Disease

Saad Ahmad*, Heath Wilt
Division of Cardiovascular Health and Disease, University of Cincinnati College of Medicine, Cincinnati, OH, USA


There is a clinically staggering burden of disease stemming from cerebrovascular events, of which a majority are ischemic in nature and many are precipitated by atrial fibrillation (AF). AF can occur in isolation or in association with myocardial or structural heart disease. In the latter case, and when considering health at an international level, congenital and acquired valve-related diseases are frequent contributors to the current pandemic of AF and its clinical impact. Guidelines crafted by the American Heart Association, American College of Cardiology, European Society of Cardiology and Heart Rhythm Society underscore the use of vitamin K antagonists (VKAs) among patients with valvular heart disease, particularly in the presence of concomitant AF, to reduce the risk of ischemic stroke of cardioembolic origin; however, the non-VKAs, also referred to as direct, target-specific or new oral anticoagulants (NOACs), have not been actively studied in this particular population. In fact, each of the new agents is approved in patients with AF not caused by a valve problem. The aim of our review is to carefully examine the available evidence from pivotal phase 3 clinical trials of NOACs and determine how they might perform in patients with AF and concomitant valvular heart disease.

Keywords: Atrial fibrillation, ischemic stroke, oral anticoagulants, valve-related heart disease.

Article Information

Identifiers and Pagination:

Year: 2016
Volume: 10
Issue: Suppl-1, M6
First Page: 110
Last Page: 116
Publisher Id: TOCMJ-10-110
DOI: 10.2174/1874192401610010110

Article History:

Received Date: 22/8/2015
Revision Received Date: 20/9/2015
Acceptance Date: 22/10/2015
Electronic publication date: 27/05/2016
Collection year: 2016

© Ahmad and Wilt; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (, which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the University of Cincinnati, Division of Cardiovascular Diseases, 231 Albert Sabin Way, Academic Health Center, Medical Sciences Building, Mail Location MLB 052, Cincinnati, OH 45267-0542, USA; Tel: (617) 780 7354; Fax: (513) 558 1255; Email:

Track Your Manuscript:


"I am very satisfied by all the services, friendly communication and the attention that was given to my manuscript. My sincere gratitude tou you and the entire team of Bentham Open"

Aristofanis Gikas
Health Centre of Kalivia, K
alivia, Attiki,

Browse Contents

Webmaster Contact:
Copyright © 2020 Bentham Open